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HEART FAILURE
procrastination leads to problems in projecting future health-
care needs and costs. Older people have more co-morbid 
conditions that complicate management but may also offer 
more opportunities for intervention; consequently, more time 
and resources are required to manage older patients well.
A detailed report on heart failure in the UK shows that the 
median age of onset has risen to about 80 years, consistent 
with improvements in the treatment of hypertension and other 
risk factors for atherosclerosis and better management of 
myocardial infarction.(5) Unfortunately, data on left ventricular 
ejection fraction (LVEF) were not available for this report. 
Analyses of the diagnostic pathway in primary care in the UK 
suggest that key investigations are often not done.(6-8)  Similar 
data from other countries are urgently required. Several large 
epidemiological surveys(9,10) and analyses of large trials(11,12) 
have recently been published that allow the demographics, 
aetiology, and management of heart failure to be compared 
internationally.
Mineralocorticoid receptor antagonists (MRAs) are effective 
anti-hypertensive agents that also improve the prognosis of 
patients with heart failure and a reduced (HFrEF) and possibly 
preserved (HFpEF) LVEF.(13)  Whether MRAs have specific 
effects on reducing other potential drivers of the progression 
to heart failure such as inflammation and fibrosis is currently 
under investigation.(14,15) Genetic propensity to greater body fat 
was associated with the risk of developing heart failure in an 
analysis on 367 703 UK Biobank participants.(16) However, the 
incidence of heart failure was only 1% (4 803 patients), the 
diagnostic criteria were not robust, and the increase in risk was 
modest (odds ratio 1.22; 95% CI 1.06 - 1.41). Further analyses 
on this population showed a strong relationship between 
cardio-respiratory fitness and grip strength and future incidence 
of heart failure.(17)  A study of 4 403 people considered for 
bariatric surgery in Sweden and followed for 22  years, found 
that 188 (9%) of the 2 003 who had surgery (25 - 35kg weight 
loss; BMI 1 year after surgery 32kg/m2) developed heart failure 
compared with 266 (13%) of 2 030 who did not (BMI after 
1 year observation 40kg/m2).(18)  Although these data suggest 
links between obesity and the risk of developing heart failure, 
it is possible that obesity just provokes similar symptoms. Once 
heart failure has developed, obesity is associated with a lower 
INTRODUCTION
The past year has brought many new concepts and an 
abundance of new data on the nature, management, and out-
come of heart failure. The pace of change is accelerating. We 
look forward to an exciting new decade of research. The prog-
nosis of cardiovascular disease is determined to a large extent 
by the ability to delay or prevent the development and pro-
gression of heart failure.(1) Accordingly, attention is shifting to 
earlier diagnosis of and intervention for heart failure. Patients 
with type-2 diabetes mellitus (T2DM)(2)  or coronary artery 
disease (CAD)(3) have a relatively good prognosis unless plasma 
concentrations of natriuretic peptides are increased, indicating 
important cardiac or renal dysfunction. Adoption of a simple 
“Universal Definition” of heart failure based on natriuretic 
peptides would facilitate early diagnosis and treatment but 
lead to an enormous increase in its prevalence and demand 
upon medical services.(4) We need to prepare for the 
impending shock.
EPIDEMIOLOGY AND PREVENTION
In cardiology, the term prevention is often used to mean 
delaying the onset of disease; in other words, procrastination. 
Failure to appreciate the difference between prevention and 
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mortality, but this may also reflect earlier diagnosis rather than 
a protective effect.(19) Randomised controlled trials (RCTs) of 
effective interventions for obesity are required to demonstrate 
whether weight loss improves symptoms (likely) and clinical 
outcomes (less certain).
A report from “the Atherosclerosis Risk in Communities” 
(ARIC) study confirmed the association between influenza 
epidemics and hospitalisations for heart failure, reinforcing 
guideline-recommendations for vaccination;(20) an RCT is 
underway.(21)  Extended follow-up (median 18.9 years) of the 
Women’s Health Initiative Hormone Therapy trials, which 
randomised 27 347 women to various hormone replacement 
regimens, showed that they had no effect on the incidence of 
HFrEF or pEF.(22) The ISCHAEMIA trial (presented at the 
American Heart Association 2019) compared strategies of 
early coronary revascularisation, predominantly percutaneous, 
with conservative management for stable CAD, some of 
whom had mild symptoms of heart failure and/or a reduced 
LVEF. Revascularisation did not reduce the risk of myocardial 
infarction or death, but increased the risk of stroke almost 
four-fold and did not reduce new-onset heart failure over the 
following 4 years.
DIAGNOSIS
The Heart Failure Association of the European Society of 
Cardiology has proposed a new scoring system for the diag-
nosis of HFpEF.(23)  Its practical utility awaits confirmation.(24) 
Simpler approaches may be preferred.(4)
CONGESTION
Congestion lies at the heart of failure.(25-27) Imaging has long 
been used to identify dilation of the atria and venous system, 
which might be termed haemodynamic congestion, for which 
natriuretic peptides are a useful biomarker.(25) More recently, 
imaging has been used to identify accumulation of fluid in tissues 
(tissue congestion),(25,28-32) which may be associated with 
increases in the biomarker, (bio)-adrenomedullin.(33)  Imaging 
and biomarkers in combination are both sensitive and specific 
for detecting a failing heart, a useful guide to the severity of 
congestion and prognosis and a potential therapeutic target 
indicating successful management. Imaging remains the pre-
ferred method for identifying the cause of heart failure. If 
congestion is central to the management of heart failure, then 
better monitoring(34)  and more effective (diuretic) interven-
tions (perhaps acetazolamide?)(35) should improve outcome 
(Figure 1).
AGE AND PROGNOSIS
Analysis of a large primary care database suggested that the 
cardiovascular (CV) prognosis of new-onset heart failure 
improved substantially between 2002 and 2014 [hazard ratio 
(HR): 0.73; 95% CI 0.68 - 0.80] for patients above and below 
the age of 80  years.(5) However, in those aged >80 years, the 
fall in CV mortality was entirely offset by non-CV mortality. In 
other words, treatment changed the way that elderly patients 
died but not overall mortality (Figure 2). Unfortunately, infor-
mation on LVEF was not available; many patients will have had 
HFpEF and, therefore, caution should be exercised in attri-
buting the reduction in CV mortality to treatment of heart 
failure. A systematic review of survey and registry data also 
suggested that the prognosis of heart failure had improved; 
important determinants of outcome were age and cardiology 
input to management.(36)  Frailty, which might be considered a 
biological rather than a chronological measure of age, may be 
an even more powerful predictor of disability and death.(37) 
Guideline-recommendations for the treatment of HFrEF do 
not discriminate by age. The Swedish Heart Failure Registry 
found that prescription of ACE inhibitors or beta-blockers to 
patients with HFrEF aged >80 years was associated with a 
lower mortality.(38,39) However, observational associations have 
many explanations other than a therapeutic effect.(40) An indi-
vidual patient-data meta-analysis of 3 RCTs of MRA (RALES, 
EMPHASIS, and TOPCAT-Americas)(13) suggested that MRAs 
exerted similar reductions in mortality (by about ~25%) for 
patients with HFrEF above and below age 75 years, but benefit 
was less certain for HFpEF.
THE DIVERSITY OF HEART FAILURE 
PHENOTYPES
Precision-medicine, which should also be accurate, requires 
patients to be classified in a way that informs management. For 
oncology, this has focused on the genetic cause, tumour 
location, and spread. For heart failure, a multi-system disorder, 
it is much more complex.(41-47) Current, therapeutically relevant 
classifications of heart failure include the severity of conges-
tion (based on symptoms, signs, blood biomarkers, and 
imaging), CAD, heart rate and rhythm and QRS duration, blood 
pressure, serum potassium, renal function, indices of iron 
deficiency, mitral regurgitation, infiltrative myocardial disease 
(e.g. amyloid), and ventricular phenotype.(41,48) Optimal manage-
ment of heart failure, with a few rare exceptions, requires only 
a modest amount of information, but this still creates many 
thousands of patient-subgroups or clusters that might have 
different therapeutic needs.(45,46) Such subgroups will increase 
exponentially with the introduction of each new class of treat-
ment. Despite this heterogeneity of substrate and wealth of 
interventions, precision-medicine is in its infancy in heart failure.
One therapeutically relevant classification of heart failure is by 
LVEF, a surrogate for left ventricular (LV) dilation. Prior to 
the 1980s, imaging of cardiac function was available only in 
expert centres. Clinical trials relied on the chest X-ray rather 
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HEART FAILURE
than the echocardiogram to support a diagnosis of heart 
failure. The success of trials such as SOLVD, MERIT, and 
CHARM, which all had a reduced LVEF as an inclusion crite-
rion, led to the adoption of LVEF <40% as the European 
Society of Cardiology (ESC) Guideline definition for HFrEF.(49) 
Values ≥40% were termed HFpEF, comprising patients with 
a mid-range or mildly-reduced (HFmrEF), normal (HFnEF) 
and, perhaps, supra-normal (HFsnEF) LVEF.(50)  Analyses of 
>350 000 routinely collected echocardiograms suggested that 
the nadir of risk, whether or not the patient has a diagnosis of 
heart failure, lies in the range 60% - 65% both for men and 
women. Interestingly, an LVEF of >70% was associated with 
similar risk as an LVEF of 30% - 40% (Figure  3).(50) The ESC 
Guidelines of 2016 introduced the concept of HFmrEF, for 2 
main reasons. Firstly, because of imprecision, an echocardio-
graphic measurement could not reliably distinguish between 
2 measurements of LVEF within 10% of each other. Creating a 
buffer-zone between HFrEF and HFnEF meant that mis-
classification was less likely. This innovation meant that a trial of 
HFpEF could not claim benefit for all patients with an LVEF 
>40% based solely on an effect in those with an LVEF 40% - 
49%. Secondly, the introduction of HFmrEF challenged the 
convention that an LVEF <40% was the correct threshold for 
HFrEF. Some analyses subsequent to the ESC 2016 Guideline 
suggest that patients with an LVEF <50% may respond to 
treatment similarly to those with an LVEF <40%.(51) However, 
this interpretation could reflect confirmation-bias amongst 
enthusiastic proponents of HFmrEF (Table  I). The evidence is 
not so consistent when looked at in its entirety, especially if 
mortality is considered a key outcome. In the future, many trials 
FIGURE 1: Two-year cause-specific mortality and non-fatal vascular events for patients with cardiovascular disease 
according to New York Heart Association (NYHA) class.
Numbers and proportions are a conceptual representation of absolute and relative risk and are not strictly evidence-based. Note that for 
patients in NYHA Class 4, interventions for sudden arrhythmic death may be ineffective or fail to lead to a meaningful prolongation of life because 
the patient is likely soon to die of worsening heart failure. CRD, congestion-related death, otherwise called death due to worsening heart failure; 
NFVE, non-fatal vascular event (e.g. myocardial infarction and stroke; note that events are more likely to be suddenly fatal as heart failure 
progresses); non-CVD, non-cardiovascular death; RSAD, resuscitatable sudden arrhythmic death; SVD, sudden vascular death; TSAD, terminal 
(non-resucitatable) sudden arrhythmic death. Reproduced with permission from ref.(59)









































CRD 0 0 3 16 9 32 27 54
TSAD <1 <1 1 5 6 21 12 24
RSAD 2 17 5 26 3 11 1 2
SVD 2 17 3 16 4 14 5 10
NFVE 4 33 3 16 2 7 1 2
Non-CVD- 4 33 4 21 4 14 4 8
CRD: Congestion-related death (heart failure, chest infection, multi-organ failure, etc.)
TSAD: Terminal sudden arrhythmic death RSAD: Resuscitatable SAD SVD: Sudden vascular death













FIGURE 2: Changes in cause-specific mortality and hospitalisations for patients with incident heart failure in the UK 
between 2002 and 2013.
Reproduced with permission from ref.(5)
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Age, <80 years 24/19 0.79 (0.71 - 0.88)
Age, ≥80 years 40/42 0.97 (0.90 - 1.06) 
P for interaction: .04
Cardiovascular
Age, <80 years 13/8 0.63 (0.54 - 0.74)
Age, ≥80 years 24/19 0.74 (0.67 - 0.83)
P for interaction: .21
Non-cardiovascular
Age, <80 years 11/12 0.96 (0.84 - 1.11
Age, ≥80 years 16/23 1.32 (1.18 - 1.49)








will probably include both HFrEF and HFmrEF, others will 
include HFmrEF, HFnEF, and HFsnEF, but NT-proBNP should 
be used routinely to stratify risk and potentially exclude low-
risk patients who have little to gain from yet another “pill’. 
Assuming we continue to use LVEF to classify patients, which 
seems likely since we cannot undo the past, then the major 
issue is where to set thresholds. For HFrEF, these have ranged 
from <25% in COPERNICUS, <30% in MADIT-II and RAFT 
to <35% - 40% for the bulk of other trials.(51) For HFpEF, LVEF 
has generally been set at >40% or >45% with no upper limit. 
Analyses of recent trials have led some to suggest that, for 
patients with an elevated NT-proBNP, the upper limit of 
LVEF for HFmrEF should be increased to 55% or even 60%, but 
this seems premature until consistency is demonstrated across 
multiple interventions and end-points and measurement pre-
cision for LVEF improves.
In a substantial observational study of patients with HFpEF 
and pulmonary hypertension, progression of right rather than 
left ventricular dysfunction was observed and was associated 
with an increased risk of atrial fibrillation (AF) and death.(52) 
Although right ventricular (RV) dysfunction is a powerful 
prognostic marker, remarkably few trials focusing on RV 
dysfunction have been done (SERENADE:  https://clinicaltrials.
gov/ct2/show/NCT03153111).
ATRIAL FIBRILLATION
About a third of outpatients, perhaps more for those with 
HFpEF,(53)  and more than half of those admitted with heart 
failure will be in AF, which is associated with an adverse prog-
nosis even after correcting for age and other risk factors.(54) 
Controversy continues over whether medical management 
focused on rate control or restoration of sinus rhythm is the 
better strategy for AF and heart failure. In practice, the strategy 
needs to be tailored to the patient. When AF is the driver of 
symptoms and worsening cardiac function, restoration of sinus 
rhythm might be appropriate but when AF reflects the pro-
gression of underlying cardiac dysfunction, it may not.(55)  For 
new-onset or paroxysmal AF associated with a clear deteri-
oration in symptoms, restoration of sinus rhythm may be 
warranted to improve symptoms. For long-standing AF and 
heart failure with markedly dilated atria, sustained restoration 
of sinus rhythm and atrial contraction is less likely. Optimal 
pharmacological management includes anticoagulation, avoiding 
toxic anti-arrhythmic agents and lenient ventricular rate 
control. Beta-blockers are the agent of choice for rate control, 
a resting day-time ventricular rate of 70 - 90bpm is pre-
ferred,(49) which may require only modest doses; digoxin should 
be used sparingly, if at all. Unfortunately, RCTs of rate vs. 
rhythm control for AF have failed to optimise the rate control 
strategy in the above fashion.
HEART FAILURE
FIGURE 3: All-cause mortality according to left ventricular ejection fraction reported on >350 000 routine echocardiograms 
stratified by age and sex.
HFmrEF, heart failure with mildly reduced ejection fraction; HFnEF, heart failure with normal ejection fraction; HFrEF, heart failure with reduced 
ejection fraction; HFsnEF, heart failure with supra-normal ejection fraction. Reproduced with permission from ref.(50)
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TABLE 1: Evidence supporting or refuting the benefits of treatments for heart failure with a left ventricular ejection fraction in 
the “mid-range” (HFmrEF: 40% - 49%).
LVEF Symptoms Hospitalisation for heart failurea 





Diuretics           
Perindopril   Improved   0.38 (0.19 - 0.75)b     
Candesartan   Improved 0.72 (0.55 - 0.95)∏ 0.76 (0.61 - 0.96) 0.81 (0.60 - 1.11) 0.79 (0.60 - 1.04) 
Irbesartan       0.98 (0.85 - 1.12)Δ     
ARNI (Sac/Val) vs. Valc   Improved 0.77 (0.58 - 1.02) 0.81 (0.64 - 1.03) 0.94 (0.69 - 1.28) NYR 
MRA (overall)c     0.76 (0.46 - 1.27) 0.72 (0.50 - 1.05) 0.69 (0.43 - 1.12) 0.73 (0.49 - 1.10) 
MRA (Americas)c     0.60 (0.32 - 1.10) 0.55 (0.33 - 0.91) 0.46 (0.23 - 0.94) 0.58 (0.34 - 0.99) 
ß-Blocker (SR) Improved   0.95 (0.68 - 1.32) 0.83 (0.60 - 1.13) 0.48 (0.24 - 0.97) 0.59 (0.34 - 1.03) 
ß-Blocker (AF) Improved   1.15 (0.57 - 2.32) 1.06 (0.58 - 1.94) 0.86 (0.36 - 2.03) 1.30 (0.63 - 2.67) 
Ivabradine            
Digoxin     0.80 (0.63 - 1.03) 0.96 (0.79 - 1.17) 1.24 (0.94 - 1.64) 1.08 (0.85 - 1.37) 
Rivaroxaban vs. aspirin   0.65 (0.40 - 1.05)   0.75 (0.53 - 1.06) 
Rivaroxaban+Aspirin vs. aspirin   0.87 (0.56 - 1.35)   0.63 (0.44 - 0.90) 
CRT 
ICD 
BNP-guided therapy       
Reduction from 
67% - 44% patients 
with an event 
Statistically significant results are shown in bold on a white background. Blank cells indicate no relevant information reported. Other data shown are not significant, although 
may not be heterogeneous with the effect in patients with a reduced left ventricular ejection fraction (HFrEF). Data for sacubitril/valsartan taken from reference for LVEF 
>42.5% - 52.5%.(98)
AF = atrial fibrillation, ARNI = angiotensin receptor-neprilysin inhibitors, BNP = brain natriuretic peptide, CRT = cardiac resynchronisation therapy, ICD = implantable cardioverter 
defibrillator, LVEF = left ventricular ejection fraction, MRA = Mineralocorticoid receptor antagonist, SR = sinus rhythm.
aRecurrent event analyses used when available.
b The PEP-CHF trial specified inclusion of patients with LVEF 40% - 49% as was LVEF >49% but did not report effects in this subgroup. However, it did report effects in patients 
with a prior myocardial infarction who were more likely to have HFmrEF.
cStronger effect in women.
A meta-analysis of RCTs of rate vs. rhythm control included 
4 trials (n = 2486) comparing pharmacological rhythm to rate 
control found no difference in mortality or thromboembolic 
events but an increase in hospitalisations, often due to recur-
rent AF, in the rhythm control group.(56) Six trials (n = 1112) 
comparing AF ablation with rate control reported reductions 
in mortality (0.51; 95% CI 0.36 - 0.74), hospitalisations (0.44; 
95% CI 0.26 - 0.76), and stroke (0.59: 95% CI 0.23 - 1.51), and 
an improved quality of life.(56)  However, none of the trials 
individually had a robust result, patients were highly selected 
and the rate control strategy was not optimal. As such, this 
meta-analysis should be considered hypothesis generating. 
Further trials are required with greater involvement of heart 
failure physicians.
IMPLANTED ELECTRICAL DEVICES
The controversy over the role of high-energy devices for heart 
failure continues. Long-term follow-up of cardiac resynchro-
nisation therapy (CRT) in a French Registry showed a low rate 
of sudden death amongst patients who received CRT-Pacing 
(without a defibrillator).(57-59) A systematic review of observa-
tional studies and RCTs reported that differences in the rate 
of sudden death with CRT-Pacing and CRT-D were narrow-
ing.(58)  RCTs comparing CRT-Pacing and CRT-D are under-
way(59)  (Figure 1). Whether myocardial scar found on cardiac 
magnetic resonance imaging identifies patients with more to 
gain from an implantable cardioverter defibrillator (ICD) is also 
under investigation(60) (CMR_GUIDE; https://clinicaltrials.gov/
ct2/show/NCT01918215). Retrospective analysis of SCD-
HeFT found that patients with T2DM did not benefit from 
an ICD.(61) An individual patient-data meta-analysis confirmed 
a reduction in sudden death with MRA.(62)  A systematic 
review identified 22 studies with post-mortem interrogation of 
ICDs; the analysis suggested that 24% of sudden deaths 
were not arrhythmic.(63)  A substantial multi-point pacing trial 
failed, so far, to show improvements in the clinical or echo-
cardiographic response to CRT.(64)
MITRAL REGURGITATION
COAPT suggested that a percutaneously delivered mitral clip 
could reduce functional (secondary) regurgitation with a sub-
sequent substantial improvement in morbidity and mortality 
that was moderately cost-effective in a US healthcare context 
(US$40  361 per life-year gained and $55  600 per quality-
adjusted life year).(65-68) Two-year follow-up of MITRA.fr 
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suggested no benefit.(69) A possible explanation for the appar-
ent discrepancy could be the ratio of the severity of LV dys-
function to the severity of mitral regurgitation. When regur-
gitation is disproportionate to the severity of LV dysfunction it 
may drive disease progression and correction may improve 
outcome.(70,71) When regurgitation is proportionate to the 
severity of LV dysfunction, fixing the mitral regurgitation may 
be less useful because myocardial dysfunction drives disease 
progression. The concept is simple and plausible, but applica-
tion in practice may be difficult. Mitral regurgitation offloads 
the LV and may mask dysfunction. It is also likely that there is 
a spectrum of primary and secondary mitral regurgitation, 
with some patients having a mixed picture. More experience 
and further data from RCTs may improve patient selec-
tion (RESHAPE-HF2:  https://clinicaltrials.gov/ct2/show/NCT
02444338). However, optimising guideline-recommended 
therapy, including diuretic dose, may cause mitral regurgitation 
secondary to dilation of the LV and mitral ring to improve or 
resolve. Other technologies for secondary mitral(72) and tricuspid 
regurgitation(73,74) are being developed.
CORONARY ARTERY DISEASE
In COMPASS (n = 27 395), 5 902 with CAD, in sinus rhythm 
and with a diagnosis of heart failure (predominantly HFpEF) 
were randomly assigned to aspirin 100mg/day, rivaroxaban 
5mg bd or aspirin and rivaroxaban 2.5mg bd.(75,76) The study 
was stopped early for benefit on the primary endpoint (a com-
posite of CV death, stroke, or myocardial infarction) with the 
combination compared with aspirin alone. Further analysis sug-
gested a reduction in all-cause mortality for patients with 
heart failure, especially HFpEF, assigned to combination therapy 
(HR: 0.63; 0.44 - 0.90) or rivaroxaban alone (HR: 0.75; 0.53 - 
1.06) with an estimated 4% absolute difference at 2 years; 
rather similar to the magnitude of effect in HFrEF for sacubitril-
valsartan(77)  or dapagliflozin(78)  (Figure  4). This suggests that 
coronary events might be an important driver of death in HFpEF 
(Figure 1), although effects of rivaroxaban on endothelial func-
tion, inflammation, and fibrosis should not be discounted. The 
analysis also suggests that those who do not have heart failure 











FIGURE 4: Effect of rivaroxaban 2.5mg bd and aspirin 100mg/day compared with aspirin alone for stable CAD, sinus 
rhythm and heart failure (predominantly heart failure with preserved ejection fraction) in COMPASS-HF.
Reproduced with permission from ref.(75)





























No. at risk No. at risk No. at risk No. at risk No. at risk No. at risk No. at risk
No heart failure at baseline 7 189 7 103 6 285 5 071 3 224 1 855 557
Rivaroxaban plus aspirin 7 147 7 045 6 202 4 978 3 224 1 837 582
Aspirin alone
Heart failure at baseline 1 963 1 922 1 613 1 218 687 355 101
Rivaroxaban plus aspirin 1 979 1 936 1 596 1 179 636 330 86
Aspirin alone
0.68 (0.53 - 0.86)
0.79 (0.68 - 0.93) 0.91 (0.76 - 1.09)
No HF: Rivaroxaban plus aspirin
HF: Rivaroxaban plus aspirin
No HF: Aspirin alone
HF: Aspirin alone
No HF: Rivaroxaban plus aspirin
HF: Rivaroxaban plus aspirin
No HF: Aspirin alone
HF: Aspirin alone
CV death, stroke or MI All-cause mortality













However, for patients with HFrEF, CAD in sinus rhythm with a 
recent hospital discharge for worsening heart failure, addition of 
rivaroxaban 2.5mg bd to background anti-platelet therapy did 
not improve overall prognosis, although a composite of vascular 
outcomes (stroke, myocardial infarction, and sudden death) 
was reduced, driven mainly by a reduction in stroke.(79,80) This 
suggests that for patients with stable CAD and more advanced 
heart failure, hospitalisations, and deaths due to worsening 




Heart failure with reduced ejection fraction
As experience in the implementation of angiotensin receptor-
neprilysin inhibitors (ARNIs) grows, both in clinical trials and in 
clinical practice, there is a strong argument to consider them as 
first-line agents, rather than angiotensin converting-enzyme 
inhibitors (ACEi) or angiotensin receptor blockers (ARB), for 
the treatment of HFrEF. In PIONEER-HF,(81) 881 patients with 
an LVEF ≤40% who were hospitalised for worsening heart 
failure were randomly assigned, without a run-in period, to 
sacubitril/valsartan or enalapril prior to discharge and followed 
for 8 weeks to determine the effect on plasma concentrations 
of NT-proBNP; about one-third had new-onset heart failure. 
Sacubitril-valsartan exerted a greater reduction in NT-proBNP. 
Reductions in markers of myocardial injury or stress, high-
sensitivity cardiac troponin-T and soluble ST2, were also 
observed. These effects appeared early after randomisation 
(within 1 - 4 weeks). Moreover, patients assigned to sacubitril/
valsartan were less likely to experience adverse outcomes 
within the first 8 weeks. TRANSITION(82) randomly assigned 
1 002 patients to pre- or post-discharge initiation of sacu-
bitril/valsartan, showing no adverse consequences to earlier 
administration.
EVALUATE(83) compared the effects of sacubitril/valsartan and 
enalapril on aortic stiffness in HFrEF most of whom were 
already chronically treated with an ACEi or ARB. After 24 
weeks treatment, no differences in aortic stiffness were 
observed, but slightly greater reductions in LV end-diastolic and 
systolic volumes were observed with sacubitril/valsartan com-
pared with enalapril, although changes in LVEF were similar. 
Mitral E-velocity and left atrial volume declined, consistent with 
a fall in left atrial pressure. PROVE-HF,(84)  an observational 
study, had similar findings and showed that most of the decline 
in NT-proBNP occurred within 14  days consistent with the 
rapid onset of clinical benefit observed with sacubitril/valsartan 
in trials and clinical practice. PRIME(85)  was an RCT (n = 118) 
comparing the effects of sacubitril/valsartan or valsartan on 
functional mitral regurgitation in patients with an LVEF between 
25% and 49% who were already receiving an ACEi or ARB. 
Those assigned to sacubitril/valsartan had greater reductions in 
mitral regurgitation and LV end-diastolic and left atrial volumes, 
but LVEF increased by a similar small amount in each group 
(about 2.5%).
Further reports from PARADIGM-HF suggest that, compared 
with enalapril, sacubitril/valsartan may improve markers of 
collagen metabolism, in particular, decreasing synthesis of type-I 
collagen, which makes an important contribution to myocardial 
stiffness.(86)  In I-PRESERVE, irbesartan (an ARB) did not affect 
collagen biomarkers compared with placebo.(87)
Heart failure with preserved ejection fraction
PARAGON-HF investigated the effect of sacubitril/valsartan 
compared to valsartan alone on morbidity and mortality in 
patients with HFpEF (defined as an LVEF >45%).(88) It was the 
first RCT since PEP-CHF(89)  to require patients to be treated 
with diuretics, the first-line treatment for the relief of symp-
toms and signs of congestion, and to have echocardiographic 
evidence of cardiac dysfunction. It was also the first large trial of 
HFpEF to require all patients to have raised plasma con-
centrations of natriuretic peptides, the most powerful, widely 
available prognostic marker in HFpEF. Sacubitril/valsartan was 
compared with valsartan rather than placebo, because many 
patients eligible for PARAGON-HF had indications for ACE 
inhibitors and ARBs such as hypertension and CAD. The only 
trial comparing valsartan to placebo in HFpEF was of modest 
size and neutral.(90)  Previous RCTs of other ARBs, including 
candesartan (CHARM-Preserved) and irbesartan (I-PRESERVE) 
failed to show substantial benefit for HFpEF.(88)  Patients had 
to tolerate, sequentially, both valsartan and sacubitril/valsartan 
at half the intended target dose before randomisation. This 
simulates clinical practice (doctors do not usually prescribe 
medicines to patients unwilling or unable to take them) and 
reduces the risk of a neutral trial-outcome due to low 
adherence. Of 10  539 patients screened, 4 822 were 
randomised.
PARAGON-HF was neutral for its primary endpoint (CV death 
or the total number of recurrent hospitalisations for heart 
failure;(91)  Figure  5). Some have argued that the  p-value was 
very close to 0.05 and that it was “almost” positive. This misses 
the point. The trial shows that the size of the potential bene-
fit of sacubitril/valsartan for HFpEF is modest, regardless of 
the  p-value and that the treatment is, overall, unlikely to be 
cost-effective. Accordingly, we should look for more effective 
treatments or, more controversially, subgroups that obtain 
greater benefit. After a median follow-up of 35 months, 23% 
of patients experienced a primary event, but the annual 
incidence of CV and all-cause mortality were, respectively, only 
about 3% and 5%, which is similar to those for previous trials 
of HFpEF and for elderly patients with resistant hypertension 
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assigned to placebo in HYVET.(92) Although <3% of patients 
were reported to have heart failure in HYVET, a combination 
of indapamide and perindopril reduced all-cause mortality and 
cut the incidence of heart failure by >50%. Many of these 
patients probably had undiagnosed HFpEF prior to randomi-
sation. Higher rates of hospitalisation for heart failure in trials 
of HFpEF compared to hypertension may well reflect ascer-
tainment bias, as clinicians who are interested or expert in the 
management of heart failure are more likely to diagnose or 
report heart failure events. Overall, these trials suggest that 
the mortality rate and possibly the rates of cardiovascular and 
all-cause hospitalisation may be similar in patients with and 
without a diagnosis of HFpEF, if they have a similar burden
of co-morbidities. However, it is also likely that many patients 
with hypertension, CAD and T2DM have undiagnosed heart 
failure.
Subgroup analysis suggested that the effect of sacubitril/val-
sartan on the primary endpoint was greater for patients with 
an LVEF below the median (57%), but this was driven almost 
entirely by an effect on hospitalisation for heart failure rather 
than on CV death.(93) The effect of sacubitril/valsartan on the 
primary endpoint was also greater for women and this was 
true throughout the studied range of LVEF, but again this was 
driven by a difference in hospitalisation for heart failure and 
not CV mortality.(94) Reductions in NT-proBNP were similar for 
each sex. Sacubitril/valsartan appeared to have a favourable 
effect on quality of life for men, but not for women. Patients 
with a recent heart failure hospitalisation may also have bene-
fited more.(95) These observations should be interpreted in the 
light of a trial that was neutral for its primary endpoint. No 
effect was observed on mortality and the benefits of treat-
ment on quality of life and hospitalisations for heart failure 
according to sex were inconsistent. In PARADIGM-HF, no 
difference in treatment effect according to sex was observed. 
A further sizeable RCT in HFpEF, PARALLAX-HF, investi-
gating the effects of sacubitril/valsartan on quality of life and 
exercise capacity will provide more evidence in 2020 (https://
clinicaltrials.gov/ct2/show/NCT03066804).
DO WOMEN AND MEN RESPOND 
DIFFERENTLY TO TREATMENT?
An analysis of 12 058 patients with HFrEF in 2 large trials found 
that women had more severe symptoms, similar LVEF but a 
substantially better prognosis than men, even after adjusting for 
key prognostic variables including aetiology and NT-proBNP 
(HR: 0.68; 0.62 - 0.89).(96) A combined analysis of PARAGON-
HF and PARADIGM-HF suggested that patients with HFrEF and 
HFpEF had similarly impaired quality of life, but that women 
HEART FAILURE
FIGURE 5: Effect of sacubitril/valsartan compared with valsartan for heart failure with preserved ejection fraction in 
PARAGON-HF.
Reproduced with permission from ref.(91)



















































Rate ratio 0.87 (0.75, 1.01)
p=0.059
Hazard ratio 0.95 (0.79, 1.16)
p=0.062†
Median follow-up 35 months Median follow-up 35 months
Valsartan (n=2389)
1 009 events, 14.6 per 100 pt-years
Sacubitril/valsartan (n=2407)
894 events, 12.8 per 100 pt-years
Valsartan - 212 patients (8.9%)
Sacubitril/valsartan - 204 patients (8.5%)
















generally reported a worse quality of life than men.(97)  In an 
observational analysis of patients with HFrEF, the BIOSTAT 
survey also found that women generally had a better prognosis 
than men, despite being prescribed lower doses of beta-
blockers and ACE inhibitors.(98)  Interestingly, men and women 
had the same heart rate, the pharmacodynamic marker of 
beta-blocker dose. For patients with HFpEF in the TOPCAT 
trial, reductions in mortality, but not hospitalisations for heart 
failure, were greater for women, although the interaction was 
statistically signif icant only for all-cause mortality.(99)  In the 
PARAGON-HF trial (HFpEF), women obtained greater benefit 
than men throughout the studied range of LVEF, but the 
difference was driven by differences in the rate of hospitalisa-
tion for heart failure rather than mortality.(94)  One obvious 
difference between men and women, on average, is size. Car-
diac resynchronisation therapy is reputed to be more effective 
in women than men, but differences disappear once adjusted 
for height.(100) Many medicines are cleared by the kidney. Esti-
mated glomerular filtration rate (eGFR) is indexed to body 
surface area (BSA), but doses of treatment are usually not. 
A woman (or small man) weighing 64kg and 160cm tall has 
BSA of 1.67m2 using the Dubois formula and a man (or large 
woman) weighing 85kg and 180cm tall has a BSA 2.05m2. If 
both have an eGFR of 60mL/kg/m2, then the woman (or small 
man) has an un-indexed eGFR of 100mL/min and the man (or 
large woman) has an un-indexed eGFR of 123mL/min. If a 
medicine is cleared by the kidney then perhaps smaller people 
require lower doses to achieve the same plasma therapeutic 
concentration and clinical benefit?
SODIUM-GLUCOSE COTRANSPORTER-2 
INHIBITORS
Sodium-glucose cotransporter protein-2 (SGLT2) is found 
mainly in the proximal renal tubule and to a lesser extent in 
other organs. SGLT1 is abundant in the intestine and myo-
cardium. SGLT2 inhibitors (SGLT2i) cause glycosuria, improving 
glycaemia, which led to their development for the treatment of 
T2DM, and an osmotic diuresis, leading to a contraction of 
plasma volume.(101,102) SGLT1 inhibitors reduce intestinal glu-
cose absorption, which can cause diarrhoea, but might have 
favourable effects on myocardial energy-utilisation.(103)  Most 
SGLT2i are highly selective, including dapaglif lozin and em-
pagliflozin, but sotagliflozin is less selective.(103) EMPA-REG 
enrolled 7 020 patients with T2DM, about 10% of whom had 
heart failure (LVEF was not measured) and showed that 
empagliflozin reduced the risk of hospitalisation for heart 
failure and mortality.(104) Within a few weeks of initiating em-
pagliflozin, body weight, and blood pressure fell and haema-
tocrit rose, consistent with a diuretic effect. Subsequent RCTs 
of other SGLT2i in T2DM had similar findings. Meta-analyses 
suggested that SGLT2i were the hypoglycaemic agents most 
likely to reduce incident heart failure,(105-107) while observational 
data raises concerns about insulin therapy.(108) A meta-analysis 
of RCTs of empagliflozin, canagliflozin, and dapagliflozin for 
T2DM, including >30  000 patients, showed benefit, at least 
for those with established CV disease.(109) For the outcome of 
hospitalisation for heart failure or CV death, the annual rate 
was about 0.6% for the 13  672 patients with multiple risk 
factors, but without established CV disease, about 3% for the 
20  650 patients with established atherosclerotic disease and 
about 6% for 3 891 patients with heart failure at baseline; the 
relative risk reductions with SGLT2i in these populations were 
16%, 24%, and 29%, respectively, without evidence of hetero-
geneity amongst agents. The largest of these trials, 
DECLARE,(110)  included 17  160 patients of whom 671 had 
HFrEF and 1 316 had HFpEF or an unspecified LVEF. In a 
subgroup analysis,(111) dapagliflozin reduced hospitalisations for 
heart failure and CV mortality for HfrEF, but not for other 
patient-groups (Figure 6).
DAPA-HF(78,112) enrolled 4 744 patients and followed them 
for a median of 18.3 months, demonstrating that addition of 
dapagliflozin to guideline-recommended therapy for HFrEF-
reduced hospitalisations for heart failure by 30% and mortality 
(mainly cardiovascular) by 18%, preventing 3 - 5 hospitalisations 
and 1 - 2 deaths per 100 patients treated per year (Figure 7). 
Patients were somewhat less likely to experience serious 
adverse events, especially renal, with dapagliflozin compared 
with placebo. The benefits appeared consistent across sub-
groups, although patients with evidence of more severe con-
gestion (worse NYHA class or higher NT-proBNP) may have 
received less benefit. Importantly, benefits were similar for 
those with and without T2DM and regardless of age.(113) 
Dapagliflozin also improved quality of life,(114)  an effect that 
was confirmed in a smaller RCT (DEFINE)(115)  that followed 
263 patients for 12 weeks; about one in 6 patients got a 
meaningful benefit, either prevention of worsening or an 
improvement in symptoms, compared with placebo.
In DAPA-HF, the placebo-corrected decline in weight between 
baseline and 8 months was 0.87kg and this was associated 
with a small fall in NT-proBNP and systolic blood pressure and 
a small increase in haematocrit and serum creatinine. These 
findings are again consistent with the belief that SGLT2i exert 
at least some of their benefits by enhancing diuresis, either 
through an osmotic effect of glycosuria or by interfering with 
sodium-hydrogen exchange in the nephron.(116) The effects of 
SGLT2i appear early, consistent with an immediate haemo-
dynamic effect. However, alternative or additional explanations 
for the effect of SGLT2i have been proposed. A small RCT 
suggested that empagliflozin stimulated production of erythro-
poietin leading to a rise in haematocrit and a fall in ferritin, a 
marker of inflammation and iron deficiency, although not 















FIGURE 6: Effect of dapagliflozin compared with placebo in type-2 diabetes mellitus in patients with heart failure with 
reduced ejection fraction, heart failure with preserved ejection fraction, or without heart failure in DECLARE.

















































































































HFrEF 671 651 638 618 600 575 553 534 521
HF/
no rEF 1 316 1 292 1 267 1 246 1 212 1 187 1 162 1 145 1 127
No HF 15 173 15 130 15 074 15 003 14 925 14 858 14 784 14 690 14 956
HFrEF 671 662 656 647 642 629 623 617 606
HF/
no rEF 1 361 1 307 1 297 1 289 1 273 1 259 1 246 1 239 1 233
No HF 15 173 15 148 15 116 15 075 15 025 14 986 14 940 14 900 14 847
HFrEF 671 660 651 640 625 606 587 571 563
HF/
no rEF 1 316 1 302 1 283 1 266 1 246 1 235 1 215 1 207 1 191
No HF 15 173 15 156 15 131 15 101 15 065 15 035 14 999 14 938 14 886
HFrEF 671 661 653 638 630 615 602 596 575
HF/
no rEF 1 316 1 306 1 289 1 273 1 253 1 228 1 205 1 183 1 168
No HF 15 173 15 134 15 055 14 965 14 859 14 766 14 649 14 542 14 407






Hospitalisation for heart failure
All-case mortality
Dapa vs. Placebo
HFrEF vs. HR 0.62 (0.45 - 0.86)
HR/no rEF vs. HR 0.88 (0.66 - 1.17)
No HF vs. HR 0.88 (0.74 - 1.03)
Dapa vs. Placebo
HFrEF vs. HR 0.55 (0.34 - 0.90)
HR/no rEF vs. HR 1.41 (0.93 - 2.13)
No HF vs. HR 1.01 (0.81 - 1.25)
Dapa vs. Placebo
HFrEF vs. HR 0.64 (0.43 - 0.95)
HR/no rEF vs. HR 0.72 (0.50 - 1.04)
No HF vs. HR 0.77 (0.60 - 0.97)
Dapa vs. Placebo
HFrEF vs. HR 0.59 (0.40 - 0.88)
HR/no rEF vs. HR 1.02 (0.75 - 1.38)



































FIGURE 7: Effect of dapagliflozin compared with placebo in patients with heart failure with reduced ejection fraction, with 
or without type-2 diabetes mellitus in DAPA-HF.












































































































































































































































2 373 2 342 2 296 2 251 2 130 1 666 1 243 672 233
Primary outcome





Hospitalisation for heart failure









Hazard ratio, 0.74 (95% CI, 0.65 - 0.85)
P<0.001
Hazard ratio, 0.82 (95% CI, 0.69 - 0.98)
Hazard ratio, 0.70 (95% CI, 0.59 - 0.83)
Hazard ratio, 0.83 (95% CI, 0.71 - 0.97)
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However, administration of exogenous erythropoietin did 
not reduce morbidity or mortality in the RED-HF trial.(118) 
Others have suggested that SGLT2i increase the production 
of ketones, which may be a more eff icient myocardial 
energy substrate, or block myocardial sodium-hydrogen 
exchanger-3, which may improve myocardial function and 
reduce fibrosis.(119,120) An RCT of empagliflozin in patients with 
T2DM but not heart failure(121)  suggested little effect on car-
diac function or remodelling; RCTs of the effects of SGLT2i 
on cardiac function in patients with HFrEF and HFpEF are 
awaited. Future trials will confirm whether the benefit observed 
in DAPA-HF is a class effect and whether they are effective for 
HFpEF or when congestion is severe.(122,123)
ACUTE HEART FAILURE
Two large RCTs of serelaxin failed to confirm the results of 
the original RELAX-AHF trial. RELAX-AHF-EU,(124)  an open-
label RCT (n = 2688), reported a similar and low rate for 
mortality (≤2%) and re-admissions for heart failure (<1%) at 
14 days for patients assigned placebo or serelaxin, despite a 
reduction in worsening heart failure at day 5 [6.7% - 4.5% 
(P < 0.008)]. The RELAX-AHF-2 trial,(125)  a double-blind RCT 
(n = 6545), reported that the rates of worsening heart failure 
in the first 5 days (about 7%) and 180-day mortality (about 
11%) were similar for placebo and serelaxin. The failure of so 
many short-term interventions for AHF may reflect failed 
therapeutic concepts, ineffective interventions, or problems 
with trial design. RCTs of AHF are difficult to implement, 
especially if conducted double-blind. Indeed, GALACTIC, a 
trial of personalised, early intensive and sustained vasodilation 
with nitrates and hydralazine, also failed to show benefit, 
calling into question the concept of vasodilator therapy for 
the routine management of acute heart failure.(126)  Many 
patients present with acute breathlessness in the middle of 
the night. It is difficult to have research staff available “24/7” 
when there is no “gateway” similar to a coronary care unit or 
catheter laboratory. Compassionate investigators may also be 
unwilling to enrol frail elderly patients who are most at risk of 
adverse outcomes. Moreover, breathlessness usually responds 
to oxygen and diuretics within hours,(127) especially for patients 
with a systolic blood pressure ≥125mmHg, as required in the 
serelaxin trials. On the other hand, patients with extensive 
peripheral oedema,(26) renal dysfunction, and a low blood pres-
sure, who often do not constitute an acute emergency have a 
poor prognosis and an unmet need for more effective inter-
ventions; pharmacological, or device.(127,128)
STEM CELL THERAPY
Intra-myocardial injection of stem cells failed to improve 
weaning from left ventricular assist devices.(130)
HEART FAILURE IN PATIENTS WITH CANCER
Interest in cardio-oncology reflects increasing survival after 
treatment for cancer, growing awareness of the CV toxicity 
associated with both established and new treatments for 
cancer, and interest in personalised risk-profiling prior to 
chemotherapy. People with cardiomyopathy-related gene 
mutations may be more prone (7.5% of those with compared 
to 1.1% of those without a titin gene mutation) to develop 
ventricular dysfunction after the administration of chemother-
apy.(131) Interruption of trastuzumab is associated with a higher 
risk of cancer recurrence in women with early invasive 
HER2+ve  breast cancer; about 60% of interruptions are for 
cardiotoxicity.(132)  An observational study showed that of 30 
women receiving HER2-targeted therapies who developed an 
LVEF of 40% - 49% and were treated prospectively with beta-
blockers and ACE inhibitors, only 3 went on to develop severe 
heart failure or a LVEF <35%.(133)  Cardiac function rarely 
returned to normal after completion of treatment, challenging 
the view that trastuzumab-related LV dysfunction is usually 
reversible. A recent study reported high rates of CV events, 
especially heart failure, amongst patients with multiple myeloma 
receiving potent proteasome inhibitors, such as carfilzomib and 
bortezomib,(134)  which were associated with much poorer 
survival. Risk factors for developing a CV event included 
elevated pre-treatment NT-proBNP or an increase during 
treatment. A systematic review of prophylactic use of renin–
angiotensin–aldosterone antagonists and beta-blockers identi-
fied 22 relevant RCTs, of which the largest had only 206 
patients,(135,136) but found no convincing evidence of clinical 
efficacy.
IMPLEMENTATION OF THERAPY
Analyses of administrative data from primary care in the UK 
suggest that implementation of therapy has improved sub-
stantially over the last decade, with 72% now prescribed a beta-
blocker, although many patients remain on less than target 
doses.(6)  Among hospital discharges in England and Wales, 
89% of those with HFrEF were discharged on a beta-blocker 
(https://www.nicor.org.uk/wp-content/uploads/2019/09/Heart-
Failure-2019-Report-final.pdf), which is very similar to that 
observed in patients with HFrEF selected for enrolment in the 
ESC-EURObservational Heart Failure Long-Term Registry.(137) 
However, an analysis of Medicare beneficiaries in the USA 
found that only 51% of patients with HFrEF were prescribed a 
beta-blocker after a first or recurrent hospitalisation for heart 
failure and only 12% received at least ≥50% of the target dose 
by one year.(138) This suggests that the organisation of care for 
HFrEF makes an important difference to treatment and, con-
sequently, outcome. However, a cluster RCT (n = 2494) of 
service redesign aiming to improve hospital-to-home transition, 
which included self-care education, a structured hospital dis-














for high-risk patients, home-visits, did not substantially improve 
patient wellbeing or outcome.(139)  An RCT (n = 110) showed 
that frequent (several times per month) visits to participating 
community pharmacies could improve medication adherence 
and wellbeing.(140)  An RCT of 450 patients found benefits of 
e-Health intervention on self-care behaviour and quality of 
life in the first 3 months after initiation but not thereafter,(141) 
with no effect on hospitalisations or mortality. There are many 
reasons why RCTs of complex interventions fail including 
inadequate power, suboptimal trial design, already excellent 
or unintended improvements in care for the control group, lack 
of long-term engagement and motivation of staff and patients, 
inclusion of patients for whom pharmacological intervention is 
largely ineffective (e.g. HFpEF), but sometimes we just have to 
admit that what should work does not. More evidence is 
required; learning from past experience.(142)
REHABILITATION
Systematic reviews suggest that exercise-based rehabilitation 
can improve patients’ wellbeing and exercise capacity and 
reduce heart failure-related and all-cause hospitalisation, but 
may not reduce mortality, despite potentially improving adher-
ence to treatment.(143-147) The best and most cost-effective 
service-model is a topic of active research.(148,149)
PALLIATIVE CARE
Morphine relieves chronic breathlessness in patients with 
chronic lung disease, but data for heart failure are sparse. An 
RCT of 45 patients failed to demonstrate important clinical 
benefits of morphine administration to patients with HFrEF or 
HfpEF, predominantly in NYHA functional class III.(150)
WITHDRAWING TREATMENT FOR HEART 
FAILURE AFTER RECOVERY
Withdrawing treatment from patients with idiopathic or 
genetically determined dilated cardiomyopathy who have 
experienced full recovery of ventricular function should be 
done with great caution, if at all.(151) Although patients with a 
recovered LVEF (HFrcEF) may have a better prognosis, it may 
still not be good.(152)  Further research is required for peripar-
tum and other specific types of cardiomyopathy. A recent 
report from an old trial (DIG), suggested that withdrawal of 
digoxin was associated with an increased risk of hospitalisa-
tion for heart failure but did not affect mortality.(153) An RCT of 
188 patients with stable heart failure from Brazil suggested 
that 75% of patients could be withdrawn from loop diuretics 
for at least 90 days without deterioration in symptoms, need 
for reinstitution of diuretic therapy, or a rise in plasma NT-
proBNP.(154)  This is in stark contrast to a smaller RCT from 
the UK, where withdrawal of diuretics and other therapies 
for 48 hours led to a doubling of plasma concentrations of 
NT-proBNP, an increase in LV and left atrial volumes and 
worsening symptoms.(155)
CONCLUSION
Great progress in the understanding and management of heart 
failure has been made over the last year. New controversies 
and new evidence challenge many old assumptions. As ever, 
some will resist progress and others will embrace it. You, the 
reader, must help our professions and patients find the correct 
balance between reckless enthusiasm and diagnostic and 
therapeutic inertia.
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